Background: Research ethics have become universal in their principles through international
Introduction

International rules for pharmacological research
Research ethics developed over the course of the 20th Century as a reaction to the discovery of scandalous conditions in which certain experiments on human beings were being carried out.
Since then, respect for individual rights has become a constant concern, and its principles have become quasi-universal in research: respect for the dignity of individuals, respect for the ICH, the objective of such harmonization is a more economical use of human, animal and material resources, and the elimination of unnecessary delay in the global development and availability of new medicines whilst maintaining safeguards on quality, safety and efficacy, and regulatory obligations to protect public health (2). Unfortunately, this standardization applies only to drugs, which is only one of the fields of clinical research.
Non pharmacological research
There are many other kinds of research. We may mention evaluation trials without 3 inserm-00377284, version 1 -21 Apr 2009 medications (medical devices, for example), physiopathological researches, and epidemiological researches. Universal principles such as the Helsinki Declaration apply to all these other kinds of "non-pharmacological" research. However, the modalities of their application vary from one country to another. This situation may entail problems for the conduct of multi-centric international studies, as well as for the publication of results if the authors and editors come from countries governed by different regulations. This situation refers particularly to so-called observational studies, i.e. collected retrospectively or prospectively, from data obtained without any additional therapy or monitoring procedure.
Issue and objectives
In fact, as underlined in a recent editorial (3), observational studies that may have respected the laws in effect in the country where they were performed, were rejected by international journals because they did not respect the laws of the country where the journal is published.
We wish to demonstrate through the study of an example from a European country that different national bodies of law can provide equivalent levels of protection that respect the same international ethical principles cited above. Our purpose in writing this article was to encourage public bodies, scientific journals, and researchers to gain a better understanding of the various sets of specific national regulations and to speak a common language. In the first example cited in the editorial (3), the authors wrote in the methods section "All tests were performed for clinical purposes using routine techniques, thus ethical approval was not sought." This statement is not in accordance with the French legislation. Indeed, the approval of an IRB/IEC is effectively not necessary for this type of study in France, but it compulsorily requires an ethical opinion because of the use of personal health data. Thus, since the authors had not solicited those two national bodies, they would have complied with neither international ethical principles nor French law; in this case, the editor was right not to accept this paper. 
The Council for International Organizations of Medical Sciences (CIOMS)
For other types of research, it is not univocal; the main international standards were drafted by the CIOMS in collaboration with the World Health Organization (WHO). In particular, the
CIOMS published International Ethical Guidelines for Biomedical Research Involving
Human Subjects (7). This document indicates that all research must benefit from both scientific and ethical expertise: "All proposals to conduct research involving human subjects 
What is the French system?
As mentioned in the introduction, observational studies require the advice of the CCTIRS and the authorization of the CNIL for the treatment of personal health data. The only studies which are exempt from this rule are those that are conducted by professional health workers on their own patients, provided that data are not transmitted to anyone else (monocentric studies), or the studies in which data are totally anonymous (i.e. without any identifier, even a number). In all other cases, persons included in the study must be personally informed through a written document of the objectives of the study and on the treatment of data, as well as on their right to object, of access and of rectification. In retrospective studies, it may happen that persons are deceased or impossible to re-contact. In such a case, it is possible to obtain a derogation to the duty of information.
The CNIL, an independent national ethical committee protecting human rights
In 1978, an independent national administrative authority, the CNIL was created to look after the protection of personal data and privacy. Among other things, its role is to authorize or reject entry (usually computerized or intended for computerization) of data identifying The CCTIRS, a committee providing expertise on methodological aspects With regard to research in the human health field, the second committee, the CCTIRS was set up in 1994. This committee is made up of 15 members qualified in the field of research in health care, in epidemiology, genetics and biostatistics. Its role is to give the CNIL advice on the reasons for the handling of personal data and on their justification with respect to the goal of research. Its expertise focuses on methodological aspects. All observational research projects must obtain the approval of this committee prior to receiving authorization from the CNIL. In 2007, the committee reviewed 608 protocols. Only 165 (27.1%) were accepted without revision, 241 (39.6%) were accepted with minor modifications, 150 (24.7%) were accepted with major revision and re-review, and 11 (1.8%) were definitely rejected. A non negligible number of protocols, 41 (6.7%), were not given a formal advice for various reasons, but most of the time because the application was not really a research protocol and the committee considered that it did not come under its responsibility.
Conclusion
Thus, the observational research regulation is very stringent in France and even goes beyond the international benchmarks. The IRB/IEC model, drafted and implemented in the context of the assessment and authorization of medical drugs, is perhaps not the most appropriate for observational research. The International Epidemiological Association (IEA), in the current draft of good epidemiological practices, suggests that "some epidemiologic research to be removed from ethics committees and instead be approved by people versed in data protection" (9), thus a model similar to the French one. Some French researchers may find the system somewhat complex and may be tempted to escape its requirements. We strongly encourage them to take all necessary regulatory steps and to specify this in their method. If 
